Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany.
Rüdiger R, Geiser F, Ritter M, Brossart P, Keyver-Paik MD, Faridi A, Vatter H, Bootz F, Landsberg J, Kalff JC, Herrlinger U, Kristiansen G, Pietsch T, Aretz S, Thomas D, Radbruch L, Kramer FJ, Strassburg CP, Gonzalez-Carmona M, Skowasch D, Essler M, Schmid M, Nadal J, Ernstmann N, Sharma A, Funke B, Schmidt-Wolf IGH. Rüdiger R, et al. Among authors: schmid m. BMC Cancer. 2021 May 10;21(1):526. doi: 10.1186/s12885-021-08141-8. BMC Cancer. 2021. PMID: 33971845 Free PMC article.
Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs) Harboring Oncogenic Potential and Is Markedly Upregulated in Hepatocellular Carcinoma.
Wang Y, Setiawan MF, Liu H, Dakal TC, Liu H, Ge F, Rudan O, Chen P, Zhao C, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, Maciaczyk J, Sharma A, Schmidt-Wolf IGH. Wang Y, et al. Among authors: schmid m. Biology (Basel). 2022 Aug 4;11(8):1174. doi: 10.3390/biology11081174. Biology (Basel). 2022. PMID: 36009801 Free PMC article.
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, Tabatabai G, Glas M, Schlegel U, Grauer O, Krex D, Schnell O, Goldbrunner R, Sabel M, Thon N, Delev D, Clusmann H, Seidel C, Güresir E, Schmid M, Schuss P, Giordano FA, Radbruch A, Becker A, Weller J, Schaub C, Vatter H, Schilling J, Winkler F, Herrlinger U, Schneider M. Zeyen T, et al. Among authors: schmid m. Trials. 2022 Jan 19;23(1):57. doi: 10.1186/s13063-021-05977-0. Trials. 2022. PMID: 35045869 Free PMC article. Clinical Trial.
3,296 results